tiprankstipranks
Advertisement
Advertisement

APLS Stock Latest News

Apellis rises 136.0%
The FlyApellis rises 136.0%
50m ago
APLS
PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD)
PremiumTipRanks Newswire
PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD)
1h ago
APLS
PYPD
Morning Movers: Marvell jumps following Nvidia investment, AI factory pact
PremiumThe Fly
Morning Movers: Marvell jumps following Nvidia investment, AI factory pact
1h ago
TE
UL
Video: Deals in food and pharmaceuticals headline busy morning of M&A
PremiumThe Fly
Video: Deals in food and pharmaceuticals headline busy morning of M&A
1h ago
UL
LLY
M&A News: Apellis Pharmaceuticals Stock (APLS) Rockets over 130% after $5.6B Biogen Rare Diseases Deal
PremiumMarket News
M&A News: Apellis Pharmaceuticals Stock (APLS) Rockets over 130% after $5.6B Biogen Rare Diseases Deal
2h ago
APLS
BIIB
Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
PremiumThe FlyBiogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
4h ago
APLS
BIIB
Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
Premium
The Fly
Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
5h ago
APLS
BIIB
Apellis price target lowered to $31 from $35 at Cantor Fitzgerald
Premium
The Fly
Apellis price target lowered to $31 from $35 at Cantor Fitzgerald
13d ago
APLS
Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls
18d ago
AA
PD
Apellis price target raised to $20 from $19 at Mizuho
PremiumThe Fly
Apellis price target raised to $20 from $19 at Mizuho
18d ago
APLS
Apellis initiated with a Buy at Roth Capital
PremiumThe Fly
Apellis initiated with a Buy at Roth Capital
18d ago
APLS
Apellis Pharmaceuticals Balances Growth With Revenue Headwinds
PremiumCompany Announcements
Apellis Pharmaceuticals Balances Growth With Revenue Headwinds
25d ago
APLS
Apellis price target raised to $20 from $19 at Mizuho
PremiumThe FlyApellis price target raised to $20 from $19 at Mizuho
26d ago
APLS
Apellis price target raised to $37 from $36 at JPMorgan
Premium
The Fly
Apellis price target raised to $37 from $36 at JPMorgan
26d ago
APLS
Apellis Pharmaceuticals Adds Mikael Dolsten to Board
Premium
Company Announcements
Apellis Pharmaceuticals Adds Mikael Dolsten to Board
29d ago
8K
APLS
Apellis appoints Mikael Dolsten to board of directors
PremiumThe Fly
Apellis appoints Mikael Dolsten to board of directors
29d ago
PFE
APLS
Apellis price target raised to $20 from $19 at Mizuho
PremiumThe Fly
Apellis price target raised to $20 from $19 at Mizuho
1M ago
APLS
Apellis price target lowered to $18 from $20 at Wedbush
PremiumThe Fly
Apellis price target lowered to $18 from $20 at Wedbush
1M ago
APLS
Apellis price target lowered to $18 from $20 at Wedbush
PremiumThe Fly
Apellis price target lowered to $18 from $20 at Wedbush
1M ago
APLS
Apellis price target lowered to $44 from $45 at Citi
PremiumThe FlyApellis price target lowered to $44 from $45 at Citi
1M ago
APLS
Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
Premium
Ratings
Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
1M ago
APLS
Apellis price target raised to $48 from $45 at H.C. Wainwright
Premium
The Fly
Apellis price target raised to $48 from $45 at H.C. Wainwright
1M ago
APLS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >